Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Seagen Inc.

Seagen Nederland

Seagen Belgium

Seagen Nordics

Seagen France

Targeting Cancer. Transforming Therapies. 
Seagen is where revolutionary science meets transformative cancer therapy. 

Seagen is committed to advancing late-stage clinical trials and expanding the development of its portfolio both in and outside the U.S. to better the health of people with cancer. We are dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells. 

We are focused on discovering, developing, manufacturing and commercializing targeted cancer therapeutics, with antibody-drug conjugates (ADCs) at our core. We work together with urgency to improve and extend the lives of people living with cancer.

Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients. ADCs are an integral part of the evolving cancer treatment paradigm with their specificity, stability, and potency. 

We are working on expanding the four approved therapies for cancer while advancing new technologies with the potential to generate multiple Investigational New Drug Applications (INDs) that include next-generation ADC technologies and other novel cancer-targeting approaches.


Pieris Pharmaceuticals

Cogent Biosciences

New Enterprise Associates

Takeda

Merck

Sofinnova Investments

Seagen

Seagen is now part of Pfizer! Together with our Pfizer colleagues, we will continue our mission of bringing life-saving treatments to people living with cancer.
 
Our scientific leadership and world-leading antibody-drug conjugate (ADC) technology combined with the scale and strength of Pfizer's capabilities and expertise, will help position Pfizer at the forefront of innovation in cancer care. 
 
We are so proud of our employees for the work that has been done over the past 25 years to positively impact the cancer community. 
 
Check out the announcement https://lnkd.in/dfq7V-tw to join us in our excitement for the future. 
 
Seagen social media accounts, including this page, will no longer be active or monitored. Please follow Pfizer for new content! 

When it comes to #cancer care, we believe it’s critical to elevate patients' voices. Through Hodgkin Hub, people like Kat, who have been impacted by #HodgkinLymphoma, share their experiences and advice on how to navigate the treatment journey.

Hear more at: bit.ly/3QRe5k4 

#ASH23

Today, we announced promising 12- and 24-month progression-free survival data for our medicine for #HodgkinLymphoma in early- and advanced-stage disease, respectively. 

Read our news release: bit.ly/3Tg8yF9

#ASH23 

As #ASH23 kicks off, we look forward to linking our latest developments in #cancer research with fellow researchers and advocates in the #bloodcancer community. Hear from members of our team and share how you work to make a difference for people impacted by cancer. #WeLink

Are you based in the New York area? Join us during #CCAM2024 for an enriching and empowering community event, bringing together patients, advocates, healthcare providers and anyone impacted by cervical cancer, on January 30, in New York City. 

Created with Genmab, the #CeMe Conversations event series aims to create a space for the community to share their unique and lived cervical cancer experiences.

Register to attend here: https://lnkd.in/e_QYhMN8

msh id	COM:SEAGEN
symbol	SGEN
name	Seagen Inc.
homepage url	https://www.seagen.com
country	US
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	3.26K
crunchbase url	-
linkedin url	-
founders	-

market cap	43.15B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.14
growth cost of revenue	0.32
growth depreciation and amortization	-0.68
growth ebitda	0.09
growth ebitda ratio	0.27
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	0.23
growth gross profit ratio	-0.01

COM:SEAGEN

Seagen Inc.

Last Close

228.90

13/12 21:00

Market Cap

43.15B

Beta: -

Volume Today

19.39M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	2.58B
cost of revenue	2.58B
depreciation and amortization	-10.66M
ebitda	-623.63M
ebitda ratio	-0.32
eps	-3.3
eps diluted	-3.3
operating expenses	2.17B
operating income	-612.97M
operating income ratio	-0.31

accounts receivables	-112.66M
capital expenditure	-77.34M
cash at beginning of period	424.83M
cash at end of period	323.49M
inventory	427.21M
working capital ttm	1.6B

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-